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Lenalidomide results in a durable complete remission
in acute myeloid leukemia accompanied by 
persistence of somatic mutations and a T-cell 
infiltrate in the bone marrow
Mechanisms of in vivo AML response and resistance to
chemotherapy remain poorly characterized. To deter-
mine whether response to lenalidomide might share fea-
tures with response to other forms of chemotherapy, we
applied immunohistochemistry and gene panel sequenc-
ing to serial samples from a patient with a remarkable 21
month clinical response. Unlike other forms of
chemotherapy, lenalidomide response was not associated
with transition through an aplastic phase, but was
accompanied by a CD8+ T-cell infiltration in the bone
marrow (BM). However, like cytarabine and decitabine
responses, we observed differential sensitivity within one
subclone and resistance within another subclone, sug-
gesting that important determinants of lenalidomide-sen-
sitivity may be cell intrinsic. These findings could be
recapitulated in a small series of additional lenalidomide
treated patients, although larger patient cohorts will be
required to determine the precise mechanistic differences
between subclones that are sensitive to lenalidomide and
those that are resistant to lenalidomide. 
Lenalidomide has been shown to induce complete
remissions in patients with AML.1-3 A wide range of
mechanisms have been proposed, including direct effects
on AML blasts,4 anti-angiogenic properties, altered signal
transduction, immunomodulatory effects that affect
cytokine production, T-cell activation, and augmentation
of NK cell function.5 To better understand mechanisms of
lenalidomide response, we carefully examined the
response of the patient with the longest morphologic
complete remission in our study.
Patient S058-034 was a 76-year-old female who pre-
sented with cytopenias (white blood cell count
3.6x103/µL, hemoglobin 6.7 g/dL, platelets 21x103/µL)
and 16% circulating myeloblasts in the peripheral blood
(PB). Her BM biopsy revealed 50% cellularity with
myeloid dysplasia affecting neutrophils and megakary-
ocytes, 26% myeloblasts by morphology, and 21%
myeloblasts via flow cytometry with an immunopheno-
type of CD34–CD33–CD117+CD56+, supporting the diag-
nosis of AML with MDS-related features. Cytogenetics
revealed a clonal abnormality:
46,XX,der(3)t(1;3)(q25;q29) [14]/46,XX[6]. FISH studies
were negative for PML-RARA, MLL, AML1-ETO, and
CBFB gene rearrangements. FLT3 and NPM1 mutation
testing was negative.
The patient was treated with a course of high-dose
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Figure 1. T-cell infiltration present in the BM at the time of CR and BM morphology over time. (A-D) Pathology of BM core biopsy at time of CR (Day 30 after
initiating lenalidomide). (A) Hematoxylin & eosin stained core biopsy that was hypercellular with increased lymphocytes. Immunohistochemistry analysis using
CD8 (B), CD4 (C) and TIA-1, a marker of cytotoxic T cells (D) demonstrates decreased CD4 to CD8 ratio in T cells with increased co-expression of TIA-1 in the
CD8+ T-cells. Original magnification X 20 objective (Panels A-D). (E) BM morphology during lenalidomide treatment determined by a 200-differential cell count.
Immature myeloid cells include promyelocytes, myelocytes, and metamyelocytes. Mature myeloid cells include bands, neutrophils, eosinophils, basophils, and
monocytes. (F-G) Peripheral blood absolute neutrophil counts (ANC), platelet counts (Plts), hematocrit (Hct), hemoglobin (Hgb), and white blood cell counts
(WBC) observed during lenalidomide therapy.
E
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induction lenalidomide (50 mg PO daily for 28 days) on a
clinical protocol (clinicaltrials.gov identifier 00546897).
Leukemia blasts rapidly cleared from her PB, and a day 15
BM biopsy revealed a morphologic leukemia free state
(MLFS) with 70% cellularity, confirmed at day 28 with a
normal karyotype, and at day 61 her PB neutrophil count
normalized (absolute neutrophil count: 1,558/µL). The
patient was then treated with twelve cycles of low dose
lenalidomide (10 mg/day PO on days 1-28 of 28-day
cycles). She remained in CRi for 21 months, which was
confirmed by BM biopsies performed at 2, 6, 9, and 12
months. During this period, the patient had persistent
thrombocytopenia (platelets 14-90x103/µL) and anemia
(Hgb 8.2-12.4 g/dL) attributed to ongoing lenalidomide
therapy, and the lenalidomide was discontinued after 12
months of therapy per protocol. She remained in remis-
sion for an additional 9 months, and then had an
extramedullary relapse involving the scalp.  A concurrent
BM biopsy revealed 90% cellularity with multilineage
dysplasia and no excess blasts. She was reinitiated on 10
mg/day of lenalidomide, but experienced disease progres-
sion with circulating peripheral blood blasts and was
transitioned to palliative care.
Like other patients achieving response to lenalidomide
on this study,1 this patient did not experience a period of
BM aplasia, suggesting that the mechanism of action of
high-dose lenalidomide is not direct myeloablation. In
this patient, clearance of blasts on day 15 was followed
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Figure 2. Differential sensitivity to lenalidomide within subclones of three patients. (A-C) The variant allele frequencies of mutations identified in patient S058-
034 could be separated into a founding clone (A), an eliminated clone (B), and an expanding clone (C). The eliminated clone and the expanding clone are imput-
ed to be subclones of the founding clone. (D) BM morphology observed in patient S046-025, who achieved CRc. (E-F) The variant allele frequencies of mutations
observed in patient S046-025 could be separated into a founding clone (E) and an eliminated clone (F). The eliminated clone is imputed to be a subclone of
the founding clone (G) BM morphology observed in patient S063-035, who maintained stable disease, although they did experience a transient reduction in
bone marrow blasts on day 15. (H-I) The variant allele frequencies of mutations observed in patient S063-035 could be separated into a founding clone (H) and
a expanding clone (I). The expanding clone is imputed to be a subclone of the founding clone. For all cases, clinical cytogenetic results are indicated above the




by an unusual lymphoid infiltrate on day 30 (41% lym-
phocytes by morphologic review).
Immunohistochemistry studies were performed on the
BM core biopsy, which revealed an increased number of
CD3+ T cells with a decreased CD4 to CD8 ratio (30%
CD4+, 70% CD8+ quantified by IHC), and the CD8+ T
cells co-expressed TIA-1 and granzyme B suggesting acti-
vated, cytotoxic effector cells (Figure 1A–D). The
CD8+bias in BM T cells persisted for 12 months, although
the proportion of BM lymphocytes normalized. T-cell
receptor gamma (TCGR) gene rearrangement studies on
day 348 showed a population of T cells with a clonal
TCR, but on a subsequent BM 2 weeks later was no clon-
al TCR population was detected. This marked, persistent
T-cell infiltration in the BM raises the possibility that a 
T-cell mediated immune response may have contributed
to this patient’s blast clearance and CRi. 
The patient’s mutation profile was assessed at eight
separate time points using a previously described
methodology and 264 gene panel.6,7 Ten somatic variants
were detected at one or more time points (8 single
nucleotide variants, one dinucleotide variant, and one
deletion, Figure 2A-C). Six variants formed a founding
clone that persisted throughout treatment (TET2, RAD21,
SRSF2, XIRP1, KIF2B, ITPR3). Three variants formed a
subclone that was eliminated by lenalidomide (GATA1,
KIF2B, NUP98). One variant was associated with a sub-
clone that expanded during lenalidomide treatment
(KRAS G12R) (Figure 2A-C). 
Two important themes emerged from this single case.
First, lenalidomide-associated morphologic responses are
not associated with complete clearance of driver muta-
tions. Instead, blast clearance correlated with elimination
of the GATA1 subclone, while the founding clone vari-
ants persisted during prolonged morphologic remission.
Secondly, response and resistance to lenalidomide may
be cell intrinsic, since differential sensitivity was
observed between the GATA1 subclone (sensitive, Figure
2B) and the KRAS subclone (resistant, Figure 2C). 
Serial BM samples were available for sequencing from
5 additional cases of AML patients treated with lenalido-
mide, who also had provided written, informed consent
for genome sequencing via a secondary banking protocol
(only this subset of patients had adequate samples for
analysis and had provided adequate consent for genomic
analysis). These additional cases were examined to deter-
mine whether these features were common to lenalido-
mide responders (2 with morphologic complete remis-
sion and 3 with stable disease). Case S046-025 achieved
a CRc that also was associated with blast clearance fol-
lowed by a lymphocyte infiltrate with increased
granzyme B+ CD8+ T-cells, the persistence of the found-
ing clone, and elimination of a subclone (Figure 2D-E).
Case S063-035 maintained stable disease, but this was
associated with a transient blast decrease, a wave of
CD3+/CD8– T-cell infiltration, and then subsequent
expansion of a FLT3 mutated subclone. The other three
cases were all associated with stable clonal architecture
(Online Supplementary Figure S1).
Five of the cases had clinically-available MHC I haplo-
type characterization. Using pVACseq,8 we found that in
three of these cases, somatic variants created tumor-spe-
cific neoepitopes with high-quality predicted binding
(IC50 < 500 nM, mutant IC50 > wild-type IC50) to patient-
specific MHC class I complexes (Online Supplementary
Table S4). In one case, S046-025 (Figure 2F) the variants
with predicted neo-epitopes were eliminated during
lenalidomide treatment, suggesting the possibility of sub-
clone-specific immunologic response. Samples necessary
to adequately evaluate for functional T- cell responses to
these neo-epitopes were not available.
Collectively, this small case series, focused on a
remarkable responder who achieved and maintained
remission for 21 months with single agent lenalidomide,
demonstrates three main findings. First, lenalidomide
response was not associated with an aplastic phase, but
was associated with an infiltration of activated CD8+ T
cells into the BM, suggesting that immune stimulation
and surveillance may play an important role in response
determination. Secondly, founding clone mutations may
persist during morphologic remission. We have previous-
ly observed similar findings following cytarabine-based
therapy,7 which suggests that both forms of therapy may
eliminate clones that emerged late during leukemic
development, but may permit the persistence of clones
that emerged early during clonal evolution. Finally, we
observed evidence of differential therapy-sensitivity
among subclones derived from the same founding clone,
which we have also observed in patients treated with
cytarabine7,9 and decitabine,10 suggesting that important
determinants of response to all three forms of
chemotherapy is cell intrinsic. Similar findings have been
recently observed in patients with non-del(5q) transfu-
sion-dependent low/intermediate-1 MDS on low dose
(10 mg) lenalidomide.11 Additional studies will be
required to better understand the differential sensitivity
and resistance that may occur within different subclones.  
Dhruv Bansal,1 Kiran Vij,1 Gue Su Chang,2
Christopher A. Miller,2 John F. DiPersio,1 Ravi Vij,1
Sharon E. Heath,1 Peter Westervelt,1 John S. Welch1* 
and Todd A. Fehniger1*
1Department of Medicine, Division of Oncology, BMT and
Leukemia Program, Washington University School of Medicine, Saint
Louis, MO and 2McDonnell Genome Institute, Washington University
School of Medicine, Saint Louis, MO, USA
*JSW and TAF contributed equally to this work
Acknowledgments: these patients were treated, and samples were
collected, as part of the investigator-initiated phase 2 clinical trial
NCT00546897, supported by Celgene.  
Funding: support was also provided by NCI Leukemia SPORE
(P50 CA171963) and the Genomics of AML Program Project grant
(P01 CA101937). TAF is supported by R01CA205239.  We thank
Greg Malnassy, Nichole Helton, and the Washington University
Tissue Procurement Core for sample storage and sample preparation.
We thank Timothy Schappe for assistance with sample collection. We
thank all BMT/Leukemia treatment teams and all patients who elected
to participate in this clinical trial.
Correspondence: tfehnige@wustl.edu/jwelch@wustl.edu
doi:10.3324/haematol.2017.184168
Information on authorship, contributions, and financial & other disclo-
sures was provided by the authors and is available with the online version
of this article at www.haematologica.org.
References
1. Fehniger TA, Uy GL, Trinkaus K, et al. A phase 2 study of high-dose
lenalidomide as initial therapy for older patients with acute myeloid
leukemia. Blood. 2011;117(6):1828-1833.
2. Fehniger TA, Byrd JC, Marcucci G, et al. Brief report Single-agent
lenalidomide induces complete remission of acute myeloid leukemia
in patients with isolated trisomy 13 Case reports. Blood. 2009;
113(5):1002-1005.
3. Blum W, Klisovic RB, Becker H, et al. Dose escalation of lenalidomide
in relapsed or refractory acute leukemias. J Clin Oncol. 2010;
28(33):4919-4925.
4. Hickey CJ, Schwind S, Radomska HS, et al. Lenalidomide-mediated
enhanced translation of C/EBPα-p30 protein up-regulates expression
haematologica 2018; 103:e272
CASE REPORTS
of the antileukemic microRNA-181a in acute myeloid leukemia.
Blood. 2013;121(1):159-169.
5. Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide
in hematological malignancies. J Hematol Oncol. 2009;2:36.
6. Welch JS, Westervelt P, Ding L, et al. Use of whole-genome sequenc-
ing to diagnose a cryptic fusion oncogene. JAMA. 2011;305(15):1577-
1584.
7. Klco JM, Miller CA, Griffith M, et al. Association between mutation
clearance after induction therapy and outcomes in acute myeloid
leukemia. JAMA. 2015;314(8):811.
8. Hundal J, Carreno BM, Petti AA, et al. pVAC-Seq: A genome-guided
in silico approach to identifying tumor neoantigens. Genome Med.
2016;8(1):11.
9. Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute
myeloid leukaemia revealed by whole-genome sequencing. Nature.
2012;481(7382):506-510.
10. Welch JS, Petti AA, Miller CA, et al. TP53 and decitabine in acute
myeloid leukemia and myelodysplastic syndromes. N Engl J Med.
2016;375(21):2023-2036.
11. Chesnais V, Renneville A, Toma A, et al. Effect of lenalidomide treat-
ment on clonal architecture of myelodysplastic syndromes without
5q deletion. Blood. 2016;127(6):749-760.
haematologica 2018; 103:e273
CASE REPORTS
